Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for ... Earthtimes (press release), UK - This Phase IIb trial assesses the impact of elagolix treatment on bone mineral density (BMD) as the primary endpoint using Dual Energy X-ray Absorptiometry ... |
Tuesday, June 17, 2008
Neurocrine Biosciences Completes 'Petal Study' Treatment Phase for ... - Earthtimes (press release)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment